| Description | Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7. |
| In vitro | 给予6-60μM Gardiquimod 显著抑制HIV-1反转录酶cDNA合成[1]。 |
| In vivo | Gardiquimod（1 mg/kg 每只小鼠；腹腔注射；每日一次，连续7天）与树突状细胞（DCs）联合应用，可增强NK细胞的抗肿瘤效果[2]。 |
| molecular weight | 313.4 |
| Molecular formula | C17H23N5O |
| CAS | 1020412-43-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (143.59 mM), Sonication is recommended. DMF: 18 mg/mL (57.43 mM) |
| References | 1. Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18. 2. Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306. |